Matt Wilsey, co-founder and CEO of Grace Science, shares a deeply personal journey after his daughter Grace was diagnosed with NGLY1 deficiency. He discusses the arduous path families face in rare disease diagnoses and the transformative advancements in genetic sequencing. Matt highlights innovative gene therapies, like AV9, aimed at treating NGLY1, and emphasizes the importance of strategic partnerships with scientists such as Nobel laureate Carolyn Bertozzi. The conversation also sheds light on navigating regulatory challenges in drug development.